Kiniksa Pharmaceuticals International vs Madrigal Pharmaceuticals
KNSA and MDGL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KNSA and MDGL compare
Kiniksa Pharmaceuticals International is the larger company, worth 1.4 times as much as Madrigal Pharmaceuticals ($14.4B against $9.9B).
Madrigal Pharmaceuticals grew revenue faster over the last twelve months (149% versus 58.9% for Kiniksa Pharmaceuticals International).
Kiniksa Pharmaceuticals International keeps more of each dollar of sales as profit, with a net margin of 9.6% compared with −25.3% at Madrigal Pharmaceuticals.
Kiniksa Pharmaceuticals International scores higher on the StockData Score (14 against 5 for Madrigal Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KNSA | MDGL |
|---|---|---|
| Size and price | ||
| Market cap | $14.4B | $9.9B |
| Share price | $92.24 | $430.36 |
| Change, 1 year | 147% | 2.1% |
| Change, 5 years | 526% | 363% |
| Beta (5Y) | 0.34 | 0.71 |
| Employees | 366 | 915 |
| StockData Score | ||
| Total score | 14 (better) | 5 |
| Valuation score | 0 | 0 |
| Growth score | 4 (better) | 1 |
| Performance score | 4 (better) | 2 |
| Health score | 6 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 95.1× | – |
| P/S | 17.1× | 7.7× (better) |
| P/B | 22.0× | 19.0× (better) |
| EV/EBITDA | 136× | – |
| P/FCF | 78.7× | – |
| FCF yield | 1.3% (better) | −2.1% |
| Fair value | $11.65 | $232.20 |
| Margin of safety | −692% | −85.3% (better) |
| Growth | ||
| Revenue growth (TTM) | 58.9% | 149% (better) |
| Net income growth (TTM) | 1584% | – |
| EPS growth (TTM) | 2325% | – |
| Profitability | ||
| Gross margin | 89.8% | – |
| Operating margin | 11.9% (better) | −25.1% |
| Net margin | 9.6% (better) | −25.3% |
| FCF margin | 21.7% (better) | −16.1% |
| Return on equity | 14.0% (better) | −53.3% |
| Return on invested capital | 44.9% (better) | −1338% |
| Financial health | ||
| Debt / equity | 0.00 | 0.65 (better) |
| Interest coverage | – | −10.2× |
| Current ratio | 3.90 (better) | 3.20 |
| Altman Z-score | 37.02 (better) | 6.72 |
| Piotroski F-score | 8 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 30.1% | 103% |
| Held by insiders | 4.7% | 24.3% |
| Insider net buying, 12 months | −$44.8M (better) | −$81.5M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 2.5% | 13.7% |
Go deeper
- KNSA stock overview
- KNSA income statement
- KNSA valuation and score
- MDGL stock overview
- MDGL income statement
- MDGL valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.